Because of the early preclinical data supporting the neuroprotective activity of CNTF, clinical trials evaluated subcutaneous recombinant human CNTF (rhCNTF) as a potential treatment for ALS (Turner et al., 2001). Here, CNTF is linked to amyotrophic lateral sclerosis.